71 results about "Colorectal tumor" patented technology

The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers (e.g., markers associated with colorectal cancer, markers associated with adenoma) in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals (e.g., humans) having a colorectal neoplasm by detecting the presence and level of indicators of colorectal neoplasia such as, for example, long DNA (e.g., quantified by Alu PCR) and the presence and level of tumor-associated gene alterations (e.g., mutations in KRAS, APC, melanoma antigen gene, p53, BRAF, BAT26, PIK3CA) or epigenetic alterations (e.g., DNA methylation) (e.g., CpG methylation) (e.g., CpG methylation in coding or regulatory regions of bmp-3, bmp-4, SFRP2, vimentin, septin9, ALX4, EYA4, TFPI2, NDRG4, FOXE1) in DNA from a stool sample obtained from the mammal.

The invention provides a primer and a probe for detecting methylation levels of BMP3 and NDRG4 in a biological sample and further provides a method and a kit for detecting the methylation levels of BMP3 and NDRG4 in the biological sample by virtue of the primer and the probe. The primer and the probe have high sensitivity and specificity; by virtue of the detection method, early diagnosis information of colorectal tumors can be provided, and a simple, convenient and feasible solution is provided for the early detection of the colorectal tumors.

A unique transcription product, CRCA-1, and alternative translation products generated therefrom, are disclosed. The transcript and its translation products are markers for colorectal cells. Screening and diagnostic reagents, kits and methods for metastasized colorectal cancer are disclosed as are reagents, kits and methods for identifying adenocarcinomas as colorectal in origin. Compounds, compositions and methods of treating patients with metastasized colorectal cancer and for imaging metastasized colorectal tumors in vivo are disclosed. Compositions and methods for delivering active compounds such as gene therapeutics and antisense compounds to colorectal cells are disclosed. Vaccines compositions and methods of for treating and preventing metastasized colorectal cancer are disclosed.

The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of colorectal cancer cells and be used as a pharmaceutical composition to inhibit the colorectal tumor growth.

A traditional Chinese medicine composition preventing and treating colorectal precancerous lesion, a preparing method thereof and applications of the composition are disclosed. The composition includes 20-60 parts of hedyotis, 9-27 parts of lightyellow sophora root, 15-45 parts of radix codonopsis, 12-36 parts of largehead atractylodes rhizome, 12-36 parts of smoked plum, 3-9 parts of rhizoma coptidis, 6-18 parts of rhizoma zingiberis praeparatum and 30-90 parts of coix seed. Prescription screening is performed according to a traditional Chinese medicine theory that is treatment based on syndrome differentiation and according to pathogenesis of intestinal cancer. Treatment mechanisms of invigorating the spleen, benefiting qi, removing heat, drying dampness, detoxifying, removing stasis, and strengthening and consolidating body resistance are adopted innovatively. Experiment results show that the composition can obviously improve AOM-DSS induced symptoms such as body mass decrease, loose stool, and hemafecia, that the composition can reduce the occurrence rate of a colorectal lesion that is mouse colon tumor, and that the composition has significant activity resisting solid colorectal tumor and intestine cytoma. Disassembled prescription experiment results show that medicine materials of the composition are irreplaceable and the composition is a scientific prescription.

Disclosed herein are panels related to the diagnosis or recognition of colon and colorectal cancer in a subject. The disclosed panels and related methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management.

The invention relates to the field of gene detection and bioinformatics. The invention discloses an application of a complex disease state evaluation method constructed based on high-throughput sequencing data and clinical phenotypes in a colorectal tumor state evaluation model. The invention discloses a method for mining colorectal cancer markers based on transcriptome data, exon group/genome data and clinical phenotypes. The invention designs a set of calculation method for constructing a colorectal cancer state evaluation model by integrating high-throughput sequencing data and clinical phenotypes, biomarkers related to colorectal cancer are screened out, and a corresponding disease state evaluation model is formed. The markers considering both accuracy and mechanism interpretability are constructed through the method and can be used for colorectal cancer prognosis evaluation, treatment effect prediction, treatment scheme assistant decision making and the like.

The invention discloses an application of FGF21 in preparation of a medicine for treating colorectal cancer, and belongs to the technical field of medicines. The FGF21 protein provided by the invention is a secretory protein composed of about 210 amino acids. The invention finds for the first time that the FGF21 has the effect of treating colorectal tumor, and cytological experiments and animal experiments prove that the FGF21 can inhibit proliferation, invasion and migration of a colorectal tumor cell line, and can obviously reduce the size of a tumor focus in a mouse model. The medicine which is used for treating colorectal cancer and is prepared by taking the FGF21 as an active substance has the effects of being good in safety, long in medicine effect lasting time, capable of protectingorgans from being damaged and capable of improving lipid metabolism disorder.

In vi tro methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. In vitro methods of determining whether or not tumor cells are colorectal in origin are disclosed. In vitro kits for practicing the methods of the invention and to reagents and compositions useful to practice the methods, for example as components in such in vitro kits of the invention are provided. Methods of and kits and compositions for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells are disclosed.

The present invention relates to nucleic acid sequences which are overexpressed in colorectal tumors which display a high level of microsatellite instability (MSI-H) vs. tumors displaying a low level of microsatellite instability (MSS), and can thus be used to identify MSI-H in a patient, and be used further to facilitate patient prognosis, monitor disease progression/regression, identify appropriate treatment regimes, and evaluate the efficacy of treatment.

The invention discloses a novel purpose of a DNA binding site CTCF_113 of a multifunctional transcriptional regulatory factor CTCF, i.e., the application thereof to prevention of a kit for early diagnosis of colorectal carcinoma. The binding site has the nucleotide sequence shown as SEQ ID NO:1. The accuracy of the CTCT binding site provided by the invention for detecting rectal adenoma and colorectal cancer is obviously higher than that of the reported DNA methylation molecular markers; the DNA binding site of the CTCF can be likely to become a biomarker for tumor treatment effect monitoring, prognosis effect evaluation and tumor molecular subtyping (such as CIMP subtyping). Generally, the invention provides a novel idea for finding the more effective tumor early stage diagnosis, treatment effect monitoring, prognosis effect evaluation and molecular subtyping molecular markers, and has the important significance on tumor prevention and treatment.

The invention relates to a preparation method and an application of a graphene-CpG. The preparation method is characterized by specifically comprising the steps of functionalizing the graphene, weighing 1mg of graphene and 5mg of PL-PEG5000-Amine (Biotin-Poly Ethylene Glycol) or PL-PEG2000-Amine and adding the two materials to a 20ml straight thick-wall glass tube, adding 5ml of distilled water to the 20ml straight thick-wall glass tube and putting the 20ml straight thick-wall glass tube in a shaker for shaking until DSPE-PEG (Distearoyl Phosphatidyl Ethanolamine-Poly Ethylene Glycol) is completely dissolved; centrifuging a graphene suspension at the room temperature for 3 hours at a rotating speed of 24000g and collecting the supernate, and recording the UV-VIS-NIR (Ultraviolet-Visual-Near Infrared) absorption spectrum of the obtained graphene solution, wherein the final concentration of the graphene is in a normal rang of 40-70mg/L; and preserving at 4 DEG C, and then bonding the graphene with an oligonucleotide CpG. The preparation method is unique and capable of obviously inhibiting the growth of the tumor of breast and the tumor of colorectum; compared with a PBS (Phosphate Buffer Solution) group, the graphene-CpG prepared by the preparation method disclosed by the invention has the advantages that the difference is significant and the growth of the tumors is obviously suppressed; besides, the preparation method has statistical significance.

The invention relates to the technical field of biological medicines, in particular to a method for detecting and identifying subspecies of fusobacterium nucleatum. The fusobacterium nucleatum is closely associated with various diseases, and recent research shows that the fusobacterium nucleatum can promote generation and development of colorectal tumors. However, an accurate and visual detection method for distinguishing different subspecies of the fusobacterium nucleatum is lacked at present. Different subspecies of the fusobacterium nucleatum are different in biological characteristic, colonization and pathogenicity, so that accurate subspecies identification has far-reaching significance for knowing the pathogenic mechanism of the fusobacterium nucleatum. According to the invention, a group of specific DNA sequences for identifying the fusobacterium nucleatum subspecies are provided, corresponding detection primers are designed, and the application of the detection primers in subspecies level detection and identification of the fusobacterium nucleatum is explained. According to the invention, the composition and the source of the subspecies of the fusobacterium nucleatum in the focus can be disclosed, and the relationship between different subspecies and diseases and related epidemiological characteristics can be explored.

The invention relates to a diagnostic marker for early colorectal cancer, wherein the diagnostic marker is circular RNA circ3823, and the nucleotide sequence of the diagnostic marker is shown in SEQ ID No.1; and an application of the circular RNA circ3823 in preparing a diagnostic tool for early colorectal cancer, wherein the tool is a kit, and the tool comprises a primer pair for amplifying a nucleic acid sequence for specifically recognizing the circular RNA circ3823. The marker can clearly and clearly characterize the occurrence of early colorectal tumor diseases, the expression of the marker in a plurality of early CRC tissue samples is significantly higher than that in a control tissue samples (normal tissues which are 5cm away from tumor tissues), and the expression of the marker ina plurality of early CRC patient serum samples is significantly higher than that in a control healthy serum sample.

The invention discloses an application of indacaterol in the treatment of colorectal cancer, and belongs to the field of molecular biology, in particular, tumor treatment. Specifically, indacaterol selected from disclosed drugs can treat colorectal cancer. The results of cell experiments and animal experiments show that indacaterol can inhibit the proliferation, invasion and migration of colorectal tumor cell lines, and can obviously reduce the size of colorectal tumors of a mouse model. At the same time, for the first time, people find that indacaterol corrects the alternative splicing of tumor cells to achieve the effects mentioned above.

The invention provides a method and system for determining colorectal tumor cells on the basis of KRAS and NDRG4 genes. The method includes: acquiring the KRAS gene and NDRG4 gene of a to-be-determined sample, and performing methylation on the NDRG4 gene; sequencing the KRAS gene and the NDRG4 gene after the methylation to obtain a KRAS gene sequencing result and a NDRG4 gene sequencing result; performing first comparison on the gene sequence of a first target position in the KRAS gene sequencing result and first reference sequence to calculate KRAS gene mutation rate; performing second comparison on the gene sequence of a second target position in the NDRG4 gene sequencing result and second reference sequence to calculate NDRG4 gene methylation linkage rate; determining whether the to-be-determined sample has colorectal tumor cells or not according to the KRAS gene mutation rate and the NDRG4 gene methylation linkage rate. By the method and system high in sensitivity, whether the sample has the colorectal tumor cells or not can be determined fast, simply and specifically.

The invention provides Zyxin gene shRNA inhibiting tumor cell proliferation and migration, a recombinant vector and application, and particularly relates to shRNA specifically silencing a Zyxin (ZYX)gene. A silencing vector of the Zyxin gene is constructed. A shRNA fragment is designed first based on the human Zyxin gene sequence, the synthesized fragment has suitable restriction sites at both ends, and the target fragment is connected to a lentiviral vector to form the core silencing vector. The constructed shRNA vector can significantly inhibit the expression of the Zyxin gene at the protein level. Furthermore, a lentivirus is used as a vector carrying shRNA, and the vector can introduce the shRNA sequence directed at the Zyxin gene into colorectal tumor cells in a targeted manner and significantly inhibit the proliferation and migration capability of the colorectal tumor cells.

The invention belongs to the technical field of biological medicine, and provides a colorectum-targeted drug-loaded exosome and application thereof, and a medicine for treating colorectal diseases. The colorectum-targeted drug-loaded exosome is obtained by introducing the medicine for treating the colorectal diseases into an exosome with a colorectal tissue targeting property; and the exosome with colorectal tissue targeting property is derived from lung cells. A colorectal tumor treatment drug contains the colorectum-targeted drug-loading exosome. Compared with the prior art, the exosome secreted by the lung cells can be enriched in the colorectum without any modification, the exosome derived from the lung cells is used, the problem of exosome yield is solved, and good application prospect is obtained; and different drugs or active molecules can be loaded by using the lung cell-derived exosome, and the treatment effect of colorectal diseases is improved and toxic and side effects of the drugs are reduced through targeted colorectal tissue administration.

The invention relates to a novel purpose of RNATES, MIP-1b and IFN-g and discloses a method for prediction of a cancer patient prognosis state by detection of RNATES, MIP-1b and IFN-g levels of three-stage colon and rectum cancer patient serum. The method creatively proves that through detection of RNATES, MIP-1b and IFN-g levels of patient serum, a prognosis state of a three-stage colon and rectum cancer patient can be predicted.

The invention provides a method and a system for determining colorectal tumor cells. The method comprises the following steps: obtaining a KRAS gene and an NDRG4 gene of a sample to be tested respectively, and methylating the NDRG4 gene; sequencing the KRAS gene and the methylated NDRG4 gene respectively to obtain a KRAS gene sequencing result and an NDRG4 gene sequencing result; performing firstcomparison on a gene sequence at a first target position in the KRAS gene sequencing result and a first reference sequence, and calculating the mutation rate of the KRAS gene; performing second comparison on a gene sequence at a second target position in the NDRG4 gene sequencing result and a second reference sequence, and calculating the methylation linkage ratio of the NDRG4 gene; based on the mutation rate of the KRAS gene and the methylation linkage ratio of the NDRG4 gene, determining whether the sample to be tested has the colorectal tumor cells. Through the method and the system, whether colorectal tumor cells exist can be quickly, simply and specifically detected, and the sensitivity is high.